Measurements of Plasma Endothelin Immunoreactivity in Healthy Cats and Cats with Cardiomyopathy
Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL, USA. Journal of Veterinary Internal Medicine
(Impact Factor: 1.88).
11/2004; 18(6):826-30. DOI: 10.1111/j.1939-1676.2004.tb02628.x
Plasma concentrations of endothelin-1 (ET-1), the most potent endogenous pressor substance discovered to date, are abnormally high in humans with congestive heart failure (CHF), and they correlate with the degree of functional impairment. We sought first to validate a human sandwich ELISA kit that targets that portion of the amino acid sequence that is identical in cats. The assay demonstrated linearity (R2 = .9968) and parallelism (P = .5339), recovery of spiked human ET-1 in cat plasma averaged 98.7%, and intraassay precision had a coefficient of variation <10%. We subsequently determined ET-1 immunoreactivity in healthy cats and in cats with myocardial disease with and without CHF, systemic thromboembolism (STE), or both. Plasma ET-1 immunoreactivity was measured in 12 healthy cats and in 28 cats with primary myocardial disease, including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), or restrictive or unclassified cardiomyopathy (RCM and UCM), respectively. Plasma ET mean (95% CI) concentrations were 0.777 (0.6536-0.924) fmol/mL in the control cats, 1.427 (0.922-2.209) fmol/mL in 12 cats with cardiomyopathy (HCM = 11, RCM/UCM = 1) but without CHF or evidence of STE, and 2.360 (1.666-3.343) fmol/mL in 16 cats with cardiomyopathy (HCM = 8, RCM/UCM = 7, DCM = 1) and CHF (n = 15) or STE (n = 4). Plasma immunoreactivity of ET-1 was significantly higher in cats with myocardial disease without CHF/STE versus normal cats (P < .05) and in cats with myocardial disease with CHF/STE versus normal cats (P < .001).
Available from: Baisan Andrei
- "This biomarker have been used to assess cardio-circulatory diseases in veterinary medicine, but with lower diagnostic value than other markers. Endothelin and Big endothelin-1, the circulating form of endothelin, were used in diagnosing dogs with dilated cardiomyopathy, congestive heart failure, myocardial ischemia , and in distinguishing between cardiac and non-cardiac diseases (Cavero et al 1990;Liu et al 1990;Prosek et al 2004a;Prosek et al 2004b;Prosek et al 2007;O'Sullivan et al 2007). Piantedosi (2009) used endothelin along with other biomarkers to assess the hemodynamic status and the class of congestive heart failure in dogs with chronic degenerative valvular disease (Piantedosi et al 2009). "
[Show abstract] [Hide abstract]
ABSTRACT: A biomarker is an indicator of a normal or pathologic process, or a pharmacologic response to a therapeutic intervention. Nowadays,
in veteriary cardiology, the most used biomarkers for assessing the pathological status of the cardio-vascular system, are B-type natriuretic peptide
and cardiac troponins. These biomarkers have been very well studied in cardiac pathology in order to assess their diagnostic potential. The
aim of the present paper was to discuss the structure, metabolism, function, applicability, reference values and variations in different diseases
and to review some practical aspects of the two cardiac biomarkers, used nowadays in small animal cardiology.
[Show abstract] [Hide abstract]
ABSTRACT: A new edge detection operator based on image features is proposed,
which analyzes edges in images for edge features in two dimensions. The
local extreme of the operator is created at the edge location and a low
value is created at the smooth region. Edges can be located by obtaining
the local extreme and a threshold of the operator response. The
detection operator is shown to be better than the Canny operator in
terms of signal-to-noise ratio and edge location accuracy
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.